Methods for treating demodex blepharitis using lotilaner formulations
AssigneeTarsus Pharmaceuticals, Inc.
InventorsBobak Robert Azamian, Douglas Michael Ackermann, Shawn D. Hickok, Joseph G. Vehige
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.
Claims20
A method for treating Demodex blepharitis, comprising topically administering directly to an ocular surface of one or more eyes of a human patient in need of treatment thereof an effective amount of an ophthalmic composition, wherein the ophthalmic composition comprises lotilaner and a pharmaceutically acceptable vehicle, and wherein the lotilaner is present at about 0.25% by weight with respect to the total weight of the composition administered.
A method for treating Meibomian gland dysfunction caused by Demodex infestation, comprising topically administering directly to one or more of the eye, eyelids, or eyelashes of a human patient in need of treatment thereof an effective amount of an ophthalmic composition, wherein the ophthalmic composition comprises lotilaner and a pharmaceutically acceptable vehicle, and wherein the lotilaner is present at about 0.25% by weight with respect to the total weight of the composition administered.
Dependencies are inferred from the claim text.